Palisade Bio, Inc. (PALI)

NASDAQ: PALI · Real-Time Price · USD
4.020
+0.040 (1.01%)
Sep 18, 2024, 4:00 PM EDT - Market closed
1.01%
Market Cap 4.76M
Revenue (ttm) n/a
Net Income (ttm) -14.19M
Shares Out 1.18M
EPS (ttm) -18.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,682
Open 4.080
Previous Close 3.980
Day's Range 3.914 - 4.140
52-Week Range 3.300 - 22.350
Beta 1.30
Analysts Strong Buy
Price Target 22.50 (+459.7%)
Earnings Date Nov 8, 2024

About PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 9
Stock Exchange NASDAQ
Ticker Symbol PALI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PALI stock is "Strong Buy" and the 12-month stock price forecast is $22.5.

Price Target
$22.5
(459.70% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

5 weeks ago - GlobeNewsWire

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end

5 weeks ago - GlobeNewsWire

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108

7 weeks ago - GlobeNewsWire

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients

7 weeks ago - GlobeNewsWire

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure t...

2 months ago - GlobeNewsWire

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstra...

2 months ago - GlobeNewsWire

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company foc...

3 months ago - GlobeNewsWire

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics

3 months ago - GlobeNewsWire

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC b...

3 months ago - GlobeNewsWire

Palisade Bio to Present at the Virtual Investor Pitch Conference

Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focus...

3 months ago - GlobeNewsWire

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local...

4 months ago - GlobeNewsWire

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

4 months ago - GlobeNewsWire

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally

4 months ago - GlobeNewsWire

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmun...

4 months ago - GlobeNewsWire

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmun...

4 months ago - GlobeNewsWire

Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end

5 months ago - GlobeNewsWire

Palisade Bio stock rallies on Strand Life Sciences partnership

Palisade Bio Inc (NASDAQ: PALI) opened roughly 50% up on Tuesday after teaming up with Strand Life Sciences.  Here's what it means for Palisade Bio stock The strategic collaboration puts its patient d...

5 months ago - Invezz

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC trea...

5 months ago - GlobeNewsWire

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Pali...

5 months ago - GlobeNewsWire

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

– Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET

5 months ago - GlobeNewsWire

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™

– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end

5 months ago - GlobeNewsWire

Palisade Bio Announces 1-for-15 Reverse Stock Split

Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel...

6 months ago - GlobeNewsWire

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chron...

7 months ago - GlobeNewsWire

Palisade Bio Provides Corporate Update and Reiterates Guidance

– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision

7 months ago - GlobeNewsWire

Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.   (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chro...

7 months ago - GlobeNewsWire